SymBio Pharmaceuticals Limited (4582)
Market cap
¥6.6B
P/E ratio
-1.3x
Symbiopharm develops drugs for rare diseases in cancer and viral infections, focusing on compounds with proven human efficacy to reduce development risks.
| Period End | Net income (Million JPY) | YoY (%) |
|---|---|---|
| Dec 31, 2025 | -4,776 | +24.59% |
| Dec 31, 2024 | -3,833 | +95.31% |
| Dec 31, 2023 | -1,963 | -266.45% |
| Dec 31, 2022 | 1,179 | -41.97% |
| Dec 31, 2021 | 2,032 | -149.68% |
| Dec 31, 2020 | -4,090 | -6.54% |
| Dec 31, 2019 | -4,376 | +58.99% |
| Dec 31, 2018 | -2,753 | -30.80% |
| Dec 31, 2017 | -3,978 | +71.96% |
| Dec 31, 2016 | -2,313 | -12.11% |
| Dec 31, 2015 | -2,632 | +135.88% |
| Dec 31, 2014 | -1,116 | -30.48% |
| Dec 31, 2013 | -1,605 | -7.39% |
| Dec 31, 2012 | -1,733 | -17.64% |
| Dec 31, 2011 | -2,105 |